Literature DB >> 2983307

Characterization of a platelet-activating factor receptor antagonist isolated from haifenteng (Piper futokadsura): specific inhibition of in vitro and in vivo platelet-activating factor-induced effects.

T Y Shen, S B Hwang, M N Chang, T W Doebber, M H Lam, M S Wu, X Wang, G Q Han, R Z Li.   

Abstract

Platelet-activating factor (PAF) is a potent lipid mediator of inflammation and asthma. Using a receptor preparation of rabbit platelet membranes, we identified a novel antagonist of PAF in the methylene chloride extract of a Chinese herbal plant, haifenteng (Piper futokadsura). The active antagonist, kadsurenone, was isolated and characterized in several in vitro and in vivo assays. It is a specific and competitive inhibitor of PAF binding to its receptor with a Ki of 5.8 X 10(-8) M vs. a Ki of 6.3 X 10(-9) M for PAF itself. It inhibits PAF-induced aggregation of rabbit platelets and human neutrophils at 2.4-24 microM, without showing any PAF agonistic activity. It potently inhibits PAF-induced degranulation of human neutrophils at 2.5-50 microM, also without any agonist activity. Kadsurenone is active orally at 25-50 mg/kg of body weight in blocking PAF-induced cutaneous permeability in the guinea pig. It also inhibits PAF-induced increases of hematocrit and circulating N-acetylglucosaminidase in the rat at greater than 10 mg/kg i.p. in a dose-dependent manner. Kadsurenone does not interfere with the function of several pharmacological mediators and receptors tested. Its structural specificity is evidenced by the poor PAF-antagonistic activities of three related structures isolated from the same haifenteng extract.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2983307      PMCID: PMC397107          DOI: 10.1073/pnas.82.3.672

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  20 in total

1.  Clearance of lysosomal hydrolases following intravenous infusion. Kinetic and competition experiments with beta-glucuronidase and N-acetyl-beta-D-glucosaminidase.

Authors:  P Stahl; J S Rodman; P Schlesinger
Journal:  Arch Biochem Biophys       Date:  1976-12       Impact factor: 4.013

2.  Structural analysis of purified platelet-activating factor by lipases.

Authors:  J Benveniste; J P Le Couedic; J Polonsky; M Tence
Journal:  Nature       Date:  1977-09-08       Impact factor: 49.962

3.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

4.  [Semi-synthesis and proposed structure of platelet-activating factor (P.A.F.): PAF-acether an alkyl ether analog of lysophosphatidylcholine].

Authors:  J Benveniste; M Tencé; P Varenne; J Bidault; C Boullet; J Polonsky
Journal:  C R Seances Acad Sci D       Date:  1979-11-26

5.  Vasoactive properties of acetyl glyceryl ether phosphorylcholine and analogues.

Authors:  D M Humphrey; L M McManus; K Satouchi; D J Hanahan; R N Pinckard
Journal:  Lab Invest       Date:  1982-04       Impact factor: 5.662

6.  Ether lipid content and fatty acid distribution in rabbit polymorphonuclear neutrophil phospholipids.

Authors:  H W Mueller; J T O'Flaherty; R L Wykle
Journal:  Lipids       Date:  1982-02       Impact factor: 1.880

7.  Vascular actions of synthetic PAF-acether (a synthetic platelet-activating factor) in the rat: evidence for a platelet independent mechanism.

Authors:  M Sánchez-Crespo; F Alonso; P Iñarrea; V Alvarez; J Egido
Journal:  Immunopharmacology       Date:  1982-04

8.  Ether phospholipids in guinea pig polymorphonuclear leukocytes and macrophages. Occurrence of high levels of 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine.

Authors:  T Sugiura; Y Onuma; N Sekiguchi; K Waku
Journal:  Biochim Biophys Acta       Date:  1982-09-14

9.  Selective acylation of lyso platelet activating factor by arachidonate in human neutrophils.

Authors:  F H Chilton; J T O'Flaherty; J M Ellis; C L Swendsen; R L Wykle
Journal:  J Biol Chem       Date:  1983-06-25       Impact factor: 5.157

10.  Acetyl glyceryl ether phosphorylcholine (platelet-activating factor) mediates heightened metabolic activity in macrophages. Studies on PGE, TXB2 and O2- production, spreading, and the influence of calmodulin-inhibitor W-7.

Authors:  H P Hartung
Journal:  FEBS Lett       Date:  1983-08-22       Impact factor: 4.124

View more
  22 in total

1.  Reversible or irreversible modification of [3H]PAF binding on rabbit platelet membranes differentiates various PAF receptor antagonists.

Authors:  M T Domingo; F Piro; C Broquet; E Auclair; P E Chabrier; P Braquet
Journal:  Lipids       Date:  1992-08       Impact factor: 1.880

Review 2.  Antiplatelet Effect of Active Components Derived from Chinese Herbal Medicine.

Authors:  Ying Zhang; Xiao-Juan Ma; Da-Zhuo Shi
Journal:  Chin J Integr Med       Date:  2015-10-10       Impact factor: 1.978

3.  Antagonism of platelet activating factor-induced chemiluminescence in guinea-pig peritoneal macrophages in differing states of activation.

Authors:  M J Parnham; C Bittner; G Lambrecht
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

4.  Determinants of inflammation test selection: in vitro or in vivo?

Authors:  M J Parnham
Journal:  Agents Actions       Date:  1986-01

Review 5.  Clinical expression of bronchial hyperreactivity in children.

Authors:  C W Bierman; G G Shapiro
Journal:  Clin Rev Allergy       Date:  1989

Review 6.  pA2 values for antagonists of platelet activating factor on aggregation of rabbit platelets.

Authors:  S R O'Donnell; C J Barnett
Journal:  Br J Pharmacol       Date:  1988-06       Impact factor: 8.739

Review 7.  PAF antagonists. Their potential therapeutic role in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Drugs       Date:  1988-02       Impact factor: 9.546

8.  Effectiveness and tolerability of CV-3988, a selective PAF antagonist, after intravenous administration to man.

Authors:  J Arnout; A van Hecken; I De Lepeleire; Y Miyamoto; I Holmes; P De Schepper; J Vermylen
Journal:  Br J Clin Pharmacol       Date:  1988-04       Impact factor: 4.335

9.  Interaction of the Paf antagonist WEB 2086 and its hetrazepine analogues with human platelets and endothelial cells.

Authors:  R Korth; M Hirafuji; C L Keraly; D Delautier; J Bidault; J Benveniste
Journal:  Br J Pharmacol       Date:  1989-10       Impact factor: 8.739

10.  Antagonism of Paf-induced oedema formation in rabbit skin: a comparison of different antagonists.

Authors:  P G Hellewell; T J Williams
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.